Clinical Trial Update: Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RO7049665 on time to relapse after steroid taper in autoimmune hepatitis was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hepatitis

Drugs mentioned

• RO7049665

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Autoimmune Hepatitis, Autoimmune Chronic Hepatitis | Phase 2 | Status: TERMINATED | Results posted: 2023-09-18